{
  "id": "601dbe2b1cb411341a00004d",
  "type": "factoid",
  "question": "What is the indication for zolmitriptan?",
  "ideal_answer": "Development of a novel zolmitriptan intracutaneous microneedle system (Qtrypta\u2122) for the acute treatment of migraine",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/14642738",
    "http://www.ncbi.nlm.nih.gov/pubmed/9399013",
    "http://www.ncbi.nlm.nih.gov/pubmed/9399012",
    "http://www.ncbi.nlm.nih.gov/pubmed/9170337",
    "http://www.ncbi.nlm.nih.gov/pubmed/9399017",
    "http://www.ncbi.nlm.nih.gov/pubmed/14743270",
    "http://www.ncbi.nlm.nih.gov/pubmed/32752932",
    "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
    "http://www.ncbi.nlm.nih.gov/pubmed/31889312",
    "http://www.ncbi.nlm.nih.gov/pubmed/9660035",
    "http://www.ncbi.nlm.nih.gov/pubmed/15992000",
    "http://www.ncbi.nlm.nih.gov/pubmed/9725543",
    "http://www.ncbi.nlm.nih.gov/pubmed/12083998",
    "http://www.ncbi.nlm.nih.gov/pubmed/10210888",
    "http://www.ncbi.nlm.nih.gov/pubmed/11200789",
    "http://www.ncbi.nlm.nih.gov/pubmed/10640260",
    "http://www.ncbi.nlm.nih.gov/pubmed/16575626",
    "http://www.ncbi.nlm.nih.gov/pubmed/9071267",
    "http://www.ncbi.nlm.nih.gov/pubmed/11594437",
    "http://www.ncbi.nlm.nih.gov/pubmed/31593739",
    "http://www.ncbi.nlm.nih.gov/pubmed/18028032"
  ],
  "snippets": [
    {
      "text": "here are many new treatment options available for migraine and more are coming. Three calcitonin gene-related peptide (CGRP) antagonist monoclonal antibodies have been approved and a 4th is due in early 2020. Small molecule CGRP receptor-blocking oral compounds, both for acute care and prevention, are also coming. Four neurostimulators are available, with others on the way. New acute treatments coming soon include the 5HT1F agonist lasmiditan, a zolmitriptan intradermal micro-needle patch, and a nasal mist sumatriptan with a permeability enhancer. F",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31889312",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Migraine has recently become a major interest to the neuroscientists. Zolmitriptan is an effective medicine used in the treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31593739",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Development of a novel zolmitriptan intracutaneous microneedle system (Qtrypta\u2122) for the acute treatment of migraine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32752932",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Zolmitriptan is a novel and highly selective 5-HT(1B/1D) receptor agonist used as an acute oral treatment for migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14642738",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan is a potent selective 5HT1B/1D receptor agonist for acute migraine therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9725543",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: The 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache. This ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16575626",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan (Zomig, formerly 311C90) is a novel, oral, acute treatment for migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399013",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan (Zomig, formerly 311C90) is a selective 5-hydroxytryptamine (5-HT)1B/1D-receptor agonist with central and peripheral activity for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9660035",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan is an effective medicine used in the treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31593739",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RATIONALE: Zolmitriptan is an anti-migraine agent with action at 5-HT1B/D receptors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11594437",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "311C90 (Zomig; zolmitriptan) is a novel, selective serotonin (5HT)1B/1D receptor agonist with both central and peripheral activity, now in late-stage clinical development for acute oral treatment of migraine. Sever",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9071267",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ion and with a tendency to recur (e.g. menstrual headaches) either naratriptan or zolmitriptan would be appropriate. Naratriptan has lower reported adverse ev",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "either rizatriptan or zolmitriptan would be appropriate for moderate and severe headache. Rizatriptan has a more rapid on",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he serotonin (5HT1B/D) agonist zolmitriptan (311C90) has been shown to be effective in the treatment of acute attacks of migraine and experimental data suggest that it may have both peripheral and central sites of action. This s",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9170337",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Naratriptan would appear to have a lower recurrent headache rate than sumatriptan, rizatriptan or zolmitriptan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Critical differences for the new TELs (naratriptan, rizatriptan and zolmitriptan) which may lead to more rational migraine management: Both rizatriptan (10 mg) and zolmitriptan (2.5 mg and 5.0 mg) have demonstrated superior efficacy to sumatriptan 100 mg, and 25 and 50 mg respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the last two years, a number of 5-HT1B/1D agonist triptans with enhanced lipophilicity (TELs) relative to the first drug of this class, sumatriptan, have been approved for marketing in most countries of the world (naratriptan, rizatriptan and zolmitriptan).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "menstrual headaches) either naratriptan or zolmitriptan would be appropriate.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11200789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Zolmitriptan is effective in the treatment of migraine associated with menses and migraine with aura",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan: a review of its use in migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " For relief of migraine headache, zolmitriptan 5mg had similar efficacy to sumatriptan 100mg for a single attack, but generally was more effective than sumatriptan 25 and 50mg for multiple attacks, in single trials",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "NCLUSION: Zolmitriptan is effective across a wide range of migraine subtypes, maintains efficacy when used in the long term and is generally well tolerated. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Zolmitriptan has also demonstrated efficacy in the treatment of persistent and/or recurrent migraine headache",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " There is some evidence to support the use of zolmitriptan in patients with migraine who have had a poor response to previous therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The efficacy of zolmitriptan appears to be maintained, with no tachyphylaxis, following repeated administration for multiple attacks of migraine over a prolonged period of time, with high headache response rates reported over all attacks",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In comparison with placebo, the incidence of persistent migraine headache is reduced by zolmitriptan and recurrent migraine headache occurs less frequently with the active treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "[Experience with intranasal zolmitriptan in cluster headache].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16575626",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " 5 mg nasal formulation of zolmitriptan is a potential new option for the symptomatic treatment of cluster headache. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16575626",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The objective is to analyse our experience with the new intranasal formulation of zolmitriptan 5 mg in the symptomatic treatment of cluster headache in daily clinical practice.P",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16575626",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan is FDA approved for the treatment of acute migraine attacks and there is recent literature demonstrating its efficacy in the acute treatment of cluster attacks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18028032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan (Zomig; formerly 311C90) is a novel 5-hydroxytryptamine (5HT)1B/1D receptor agonist with proven efficacy in the acute treatment of migraine with or without preceding aura.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399012",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan is a suitable first-line drug for acute treatment for migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15992000",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan, a selective 5-HT(1B/D) agonist was developed for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14743270",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "lmitriptan. Zolmitriptan is effective in the treatment of migraine associated with menses and migrain",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10473025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan is effective in the treatment of migraine associated with menses and migraine with aura.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12083998",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan, a 5-hydroxytryptophan(1B/1D) receptor agonist, is once such drug that is used in acute migraine therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18028032",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan has also shown efficacy in the treatment of persistent and/or recurrent migraine headache.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12083998",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10640260",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Zolmitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10210888",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan is a 5-HT1B/1D receptor agonist for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10640260",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Zolmitriptan (Zomig, formerly 311C90) is a novel, oral antimigraine drug that is consistently effective and well tolerated in the acute treatment of migraine headache and its associated symptoms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399017",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "migraine, headache"
}